Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review

Abstract

ObjectiveTo assess the efficacy of active treatment targeted at underlying disease (TTD)/potentially curative treatments versus palliative care (PC) in improving overall survival (OS) in terminally ill patients.DesignWe performed a systematic review and meta-analysis of randomised controlled trials (RCT). Methodological quality of included RCTs was assessed using the Cochrane risk of bias tool.Data sourcesMedline and Cochrane databases were searched, with no language restriction, from inception to 19 October 2016.Eligibility criteria for selecting studiesAny RCT assessing the efficacy of any active TTD versus PC in adult patients with terminal illness with a prognosis of <6-month survival were eligible for inclusion.ResultsInitial search identified 8252 citations of which 10 RCTs (15 comparisons, 1549 patients) met inclusion criteria. All RCTs included patients with cancer. OS was reported in 7 RCTs (8 comparisons, 1158 patients). The pooled results showed no statistically significant difference in OS between TTD and PC (HR (95% CI) 0.85 (0.71 to 1.02)). The heterogeneity between pooled studies was high (I2=62.1%). Overall rates of adverse events were higher in the TTD arm.ConclusionsOur systematic review of available RCTs in patients with terminal illness due to cancer shows that TTD compared with PC did not demonstrably impact OS and is associated with increased toxicity. The results provide assurance to physicians, patients and family that the patients' survival will not be compromised by referral to hospice with focus on PC.

Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study

“…Poor performance status patients (ECOG-PS ≥ 2) usually tolerate chemotherapy poorly, with increased toxicity compared to patients with ECOG-PS 0-1. 46,47 In the present study, poor performance status was also a predictor of toxicity in gastrointestinal cancer patients. This underscores the need to identify clinical characteristics of poor performance status patients, avoiding overtreatment.…”

“…The present univariate model only suggested a maintained association between cachexia and ECOG with toxicities when the model was adjusted in multivariable analyses. Poor performance status patients (ECOG‐PS ≥ 2) usually tolerate chemotherapy poorly, with increased toxicity compared to patients with ECOG‐PS 0–1 . In the present study, poor performance status was also a predictor of toxicity in gastrointestinal cancer patients.…”

Inappropriate medication use and polypharmacy in end-stage cancer patients: Isn't it the family doctor's role to de-prescribe much earlier?

“…A systematic review on terminally ill cancer patients showed that active, potentially curative treatments had less efficacy in improving overall survival and increased toxicity, as compared with palliative care approaches. 39 Prognosis of ESC patients who received chemotherapy was not improved, 40 and they were more likely to die in intensive care units rather than in their own homes. 41 Considering physician and patient's awareness to the adverse events of chemotherapy, it is surprising that almost a quarter of our terminally ill patients were still receiving oncological therapies 2 weeks before death.…”

Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study

“…[4][5][6] Realistic estimates of overall survival are particularly important for patients with a diagnosis of cancer who need to make decisions about the risks and benefits of active versus supportive treatment (eg, whether to have surgery, chemotherapy, radiotherapy, or palliative care). 7 Current evidence suggests that issues around survival are only discussed properly in approximately 30% of cases. 8 This may reflect a lack of robust information on survival, which takes account of patient characteristics and the likely effect of different treatments.…”